The Weizmann Institute of Science in Rehovot, Israel, today announced the installation of the Biospec® 15.2 Tesla USR™ preclinical ultra-high field magnetic resonance imaging (MRI) instrument from Bruker. The new instrument is installed in the Daniel Wolf building of the Department of Chemical Research, and is used by the MRI Biosensors laboratory, led by Dr. Bar-Shir, and the laboratory of Professor Neeman, to open new frontiers in molecular and microscopic imaging, adding to the team's existing world-class MRI instruments.
The new 15.2 Tesla MRI is one of the latest MRI instruments from Bruker to be installed on site in Israel, alongside the Bruker BioSpec 4.7 Tesla MRI and the Bruker 400WB (wide-bore) spectrometer. The instrument will enable multiplexed imaging, not previously available to the institute in its current MRI capabilities, with the aim to develop, optimize, and implement genetically engineered reporter systems for MRI with artificial "multicolor" characteristics. The extremely high spatial resolution of the 15.2 Tesla MRI will increase the number of artificial colors that can be observed, and open new avenues for monitoring biological multiplexity.
The Weizmann Institute is a world-class institution in MRI research, with specialized capabilities in the Bar-Shir Laboratory and the Neeman Laboratory. The Neeman lab combinescutting-edge preclincal MRI experience with the ability to monitor in vivo biological variables non-invasively in order to track the progression of diseases, such as cancer, or of intervention in the same living animal, which greatly improves biological and translational relevance.
The Bar-Shir lab aims to develop new biosensors and tracers for MRI applications by using synthetic chemistry, nanotecnology and molecular biology approaches. Such biosensors will help scientists around the world to study biological events longitudinally and non-invasively in deep tissues of live animals.
Dr. Amnon Bar-Shir, Department of Organic Chemistry at theWeizmann Institute of Science, stated: "We feel this new installation will be a real game changer for our facility. The new 15T MRI will give us superior spectral resolution and boosts the signal-to-noise ratio for higher spatial resolution and faster measurements. The new instrument will facilitate the research of our world-class team and will reinforce Weizmann's position as one of the premier centers in the world for MR research."
Dr. Wulf I. Jung, President of the Bruker BioSpin Preclinical Imaging division, added: "We are extremely pleased to partner with the Weizmann Institute and provide the enabling MRI research tools they need to advance the scientific understanding of the biomolecular processes of many diseases, as well as the understanding of advanced bio-materials that will impact many emerging diagnostic and therapeutic approaches."
The BioSpec® product series is designed for the emerging market of preclinical and molecular MR imaging and MRI research. State-of-the-art MRI CryoProbe™ technology combined with ultra-high field USR magnets deliver high spatial resolution in vivo at highest stabilty, thus enabling customers to come closer to the molecular and cellular level research they desire.
Due to the largest preclinical portofolio of sequences and in vivo optimized measurement protocols, virtually any small animal MR imaging application in life science, biomedical and preclinical research can be conducted.
Source:
Tackling the Global Issue of New Psychoactive Substances